Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors
- PMID: 18565342
- DOI: 10.1016/j.jmb.2008.04.054
Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors
Abstract
It has been shown that L-731988, a potent integrase inhibitor, targets a conformation of the integrase enzyme formed when complexed to viral DNA, with the 3'-end dinucleotide already cleaved. It has also been shown that diketo acid inhibitors bind to the strand transfer complex of integrase and are competitive with the host target DNA. However, published X-ray structures of HIV integrase do not include the DNA; thus, there is a need to develop a model representing the strand transfer complex. In this study, we have constructed an active-site model of the HIV-1 integrase complexed with viral DNA using the crystal structure of DNA-bound transposase and have identified a binding mode for inhibitors. This proposed binding mechanism for integrase inhibitors involves interaction with a specific Mg(2+) in the active site, accentuated by a hydrophobic interaction in a cavity formed by a flexible loop upon DNA binding. We further validated the integrase active-site model by selectively mutating key residues predicted to play an important role in the binding of inhibitors. Thus, we have a binding model that is applicable to a wide range of potent integrase inhibitors and is consistent with the available resistant mutation data.
Similar articles
-
Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.Biochemistry. 2007 Sep 25;46(38):10776-89. doi: 10.1021/bi7006542. Epub 2007 Aug 29. Biochemistry. 2007. PMID: 17725323
-
Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.Biochem Biophys Res Commun. 2007 Nov 23;363(3):554-60. doi: 10.1016/j.bbrc.2007.08.199. Epub 2007 Sep 14. Biochem Biophys Res Commun. 2007. PMID: 17889829
-
Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.FEBS Lett. 2010 Apr 16;584(8):1455-62. doi: 10.1016/j.febslet.2010.03.016. Epub 2010 Mar 16. FEBS Lett. 2010. PMID: 20227411
-
Characterization and structural analysis of HIV-1 integrase conservation.AIDS Rev. 2009 Jan-Mar;11(1):17-29. AIDS Rev. 2009. PMID: 19290031 Review.
-
Resistance to HIV-1 integrase inhibitors: A structural perspective.Drug Resist Updat. 2010 Aug-Oct;13(4-5):139-50. doi: 10.1016/j.drup.2010.05.001. Epub 2010 Jun 8. Drug Resist Updat. 2010. PMID: 20570551 Review.
Cited by
-
Structure-based modeling of the functional HIV-1 intasome and its inhibition.Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15910-5. doi: 10.1073/pnas.1002346107. Epub 2010 Aug 23. Proc Natl Acad Sci U S A. 2010. PMID: 20733078 Free PMC article.
-
Structural biology of retroviral DNA integration.Virology. 2011 Mar 15;411(2):194-205. doi: 10.1016/j.virol.2010.12.008. Epub 2011 Jan 8. Virology. 2011. PMID: 21216426 Free PMC article. Review.
-
HIV-1 Integrase Strand Transfer Inhibitors: Novel Insights into their Mechanism of Action.Retrovirology (Auckl). 2008 Nov 5;2:11-16. doi: 10.4137/rrt.s1081. Retrovirology (Auckl). 2008. PMID: 19915684 Free PMC article.
-
Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.PLoS One. 2013 Oct 16;8(10):e77448. doi: 10.1371/journal.pone.0077448. eCollection 2013. PLoS One. 2013. PMID: 24146996 Free PMC article.
-
Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited.Bioorg Med Chem Lett. 2010 Jun 1;20(11):3275-9. doi: 10.1016/j.bmcl.2010.04.048. Epub 2010 Apr 21. Bioorg Med Chem Lett. 2010. PMID: 20457521 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Chemical Information